Apimeds Pharmaceuticals US (APUS) EBIT (2024 - 2025)
Apimeds Pharmaceuticals US's (APUS) quarterly EBIT came in at -$7.0 million in Q4 2025, down 2454.32% YoY from $299026.3 in Q4 2024, and down 281.73% on a QoQ basis from -$1.8 million in Q3 2025.
Apimeds Pharmaceuticals US (APUS) EBIT (2024 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has 2 years of EBIT data on file, last reported at -$7.0 million in Q4 2025.
- Quarterly EBIT fell 2454.32% year-over-year to -$7.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$11.9 million (down 834.25% YoY) and the FY2025 annual result came in at -$11.9 million, down 834.25% from the prior year.
- EBIT fell to -$7.0 million in Q4 2025, from -$1.8 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$271726.0 in Q1 2024 to a low of -$7.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | -231.00 Mn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 837.00 Mn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 1.26 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 330.80 Mn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 6.30 Mn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 151.50 Mn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 248.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Apimeds Pharmaceuticals US | 7.12 Mn | 7.12 Mn | - | -6.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -7.04 Mn |
| Sep 30, 2025 | -1.84 Mn |
| Jun 30, 2025 | -2.66 Mn |
| Mar 31, 2025 | -364,368.00 |
| Dec 31, 2024 | -275,613.00 |
| Sep 30, 2024 | -299,999.00 |
| Jun 30, 2024 | -427,757.00 |
| Mar 31, 2024 | -271,726.00 |